ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 7,750,000 shares, a growth of 40.7% from the June 30th total of 5,510,000 shares. Based on an average daily volume of 852,600 shares, the short-interest ratio is currently 9.1 days. Approximately 26.0% of the shares of the stock are sold short.

ALX Oncology Stock Down 0.8 %

Shares of NASDAQ ALXO opened at $6.05 on Monday. The firm’s 50-day moving average price is $8.22 and its 200-day moving average price is $12.15. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $315.21 million, a price-to-earnings ratio of -1.63 and a beta of 1.06. ALX Oncology has a 12-month low of $3.94 and a 12-month high of $17.83.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.16. On average, equities research analysts anticipate that ALX Oncology will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on ALXO shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, May 29th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research report on Monday, June 10th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Activity

In other news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the sale, the insider now directly owns 330,349 shares in the company, valued at approximately $5,265,763.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ALX Oncology news, insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the sale, the insider now owns 330,349 shares in the company, valued at approximately $5,265,763.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $15.92, for a total transaction of $318,400.00. Following the completion of the sale, the insider now owns 604,205 shares in the company, valued at approximately $9,618,943.60. The disclosure for this sale can be found here. Insiders have sold 78,469 shares of company stock worth $873,346 in the last three months. Company insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in ALX Oncology by 31.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 104,966 shares of the company’s stock worth $633,000 after purchasing an additional 25,199 shares during the period. California State Teachers Retirement System raised its position in ALX Oncology by 413.8% in the 1st quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock worth $254,000 after purchasing an additional 18,360 shares during the period. Redmile Group LLC raised its position in ALX Oncology by 18.2% in the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after purchasing an additional 667,245 shares during the period. EntryPoint Capital LLC purchased a new stake in ALX Oncology in the 1st quarter worth about $32,000. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in ALX Oncology in the 1st quarter worth about $27,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.